AQR CAPITAL MANAGEMENT LLC
Position in MLYS — Mineralys Therapeutics, Inc.
CIK 1167557
Greenwich, CT
Position in MLYS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$4,114,555
+$75,819 QoQ
Shares Held
152,504
+2.3% QoQ
Ownership
0.173%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#72
of 224 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 86%
Shared 0%
None 14%
Common Shares in MLYS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026AQR CAPITAL MANAGEMENT LLC holds $5,647,082,401 across 216 Biotechnology names. MLYS ranks #87 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,126,080 | $702,155,918 | |
| 2 | INCY |
Incyte Corp
|
5,320,901 | $603,177,333 | |
| 3 | EXEL |
Exelixis, Inc.
|
11,023,943 | $599,812,735 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
1,522,568 | $366,893,205 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
5,699,541 | $326,127,732 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
616,170 | $306,070,117 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
1,295,450 | $242,611,869 | |
| 8 | RPRX |
Royalty Pharma plc
|
4,305,412 | $241,404,446 |
All Filings in MLYS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,114,555 | 152,504 | Shares | Other | 2026-08-14 | |
| 2026-03-31 | $4,038,736 | 149,086 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $2,260,864 | 62,300 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $687,183 | 18,122 | Shares | Other | 2025-11-14 | |
| 2025-06-30 | $377,498 | 27,901 | Shares | Other | 2025-08-14 | |
| 2025-03-31 | $549,685 | 34,615 | Shares | Defined | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||